The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1496
Pimavanserin (Nuplazid) for Parkinson's Disease Psychosis
The full article is available to subscribers Subscriber Login   

The FDA has approved the atypical antipsychotic pimavanserin (Nuplazid – Acadia) for treatment of hallucinations and delusions associated with Parkinson's disease. It is the first drug to be approved in the US for this indication.

PARKINSON'S DISEASE PSYCHOSIS — Hallucinations and delusions occur in up to 60% of patients with Parkinson's disease.1 Low doses of clozapine (Clozaril, and others) have been effective for treatment of these symptoms, but even in low doses clozapine can cause agranulocytosis, somnolence, and other significant toxicity.2,3 Low-dose quetiapine has been used off-label to treat Parkinson's disease psychosis, but it has not been effective in controlled trials.4,5 Both clozapine and quetiapine block dopamine receptors and could exacerbate the motor symptoms ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Pimavanserin (Nuplazid) for Parkinson's Disease Psychosis
Article code: 1496b
 Electronic, downloadable article - $25